title: [Carotid barostimulation in the treatment of resistant hypertension].
abstract: The autonomic nervous system plays a pivotal role in the development of hypertension and organ damage complicating hypertension. The US company CVRx developed medical devices (first generation Rheos™ and second generation Neo™) aimed to electronically activate baroreceptors, which signal the brain to orchestrate a multisystemic response to address chronic diseases such as hypertension and heart failure. This review presents available clinical trial data on carotid barostimulation in the treatment of resistant hypertension.
authors.affiliation: Inserm U1116, centre d'investigations cliniques-plurithématique 14-33, 4, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France; Institut lorrain du cœur et des vaisseaux Louis-Mathieu, CHRU de Nancy, 4, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France; Université de Lorraine, 34, cours Léopold, 54000 Nancy, France; Association Lorraine de traitement de l'insuffisance rénale (Altir), 4, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France; F-CRIN INI-CRCT (Cardiovascular and renal clinical trialists), 4, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. Electronic address: p.rossignol@chru-nancy.fr.
authors.forename: Patrick
authors.initials: P
authors.lastname: Rossignol
mesh_terms: D002339:Carotid Arteries; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D004599:Electric Stimulation Therapy / Q000295:instrumentation* / Q000379:methods; D004867:Equipment Design; D006333:Heart Failure / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D011311:Pressoreceptors; D012720:Severity of Illness Index; D016896:Treatment Outcome
keywords: Barostimulation carotidienne; Carotid barostimulation; Hypertension artérielle résistante; Resistant hypertension